Comparison · NCT03945019-b7fc2e91
CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CT-P13 SC 120 mg vs Placebo: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54. Trial comparisons, record NCT03945019-b7fc2e91. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03945019-b7fc2e91
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.623 | 0.559 | 0.683 | wilson | |
| Risk in group 2 | 0.321 | 0.242 | 0.413 | wilson | |
| Risk difference, group 1 minus group 2 | 0.302 | 0.191 | 0.401 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.94 | 1.46 | 2.58 | log | |
| Odds ratio, group 1 over group 2 | 3.49 | 2.17 | 5.63 | log | |
| Number needed to treat, for one more participant with the outcome on CT-P13 SC 120 mg than on Placebo | 3.31 | 2.49 | 5.25 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CT-P13 SC 120 mg | CT-P13 SC 120 mg | 144 | 231 | OG000 |
| Group 2 | Placebo | Placebo | 36 | 112 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54
- Description
Clinical remission was defined as an absolute Crohn's Disease Activity Index (CDAI) score of \<150 points.~The total CDAI scores range from 0 to over 600 with higher scores indicating increased severity of disease. The index is the sum of 8 components; number of liquid or very soft stools, abdominal pain, general well-being, CD complications, taking antidiarrheal drugs, abdominal mass, hematocrit, and weight.~Patients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.
- Time frame
- Week 54
- Population
- All-randomized population
Source ClinicalTrials.gov
Trial
- Title
- CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
- NCT number
- NCT03945019
- Phases
- PHASE3
- Conditions
- Crohn's Disease
- Interventions
- CT-P13 SC (Infliximab), Placebo SC
- Lead sponsor
- Celltrion
- Results first posted
- 2023-10-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03945019?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03945019-b7fc2e91